BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of purchasers of the securities of Prosensa Holding B.V. (“Prosensa” or the “Company”) (NASDAQ:RNA) concerning possible violations of federal securities laws. The investigation focuses on allegations that the Company’s Registration Statement and Prospectus issued in connection with Prosensa’s June 28, 2013, initial public offering were materially false and/or misleading.

Prosensa is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders, primarily rare neuromuscular and neurodegenerative disorders, including myotonic dystrophy, Huntington’s disease and Duchenne muscular dystrophy, or DMD. The Company’s lead RNA-based product candidate is drisapersen, an investigational treatment for muscle wasting caused by DMD. The investigation is related to allegations that the Registration Statement and Prospectus misrepresented or failed to disclose material facts concerning drisapersen’s efficacy and prospects for marketing approval.

If you purchased Prosensa shares pursuant or traceable to the Company’s initial public offering, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll-Free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.